Search

Zai Lab Ltd ADR

Chiusa

SettoreSettore sanitario

26.16 -2.68

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.29

Massimo

26.92

Metriche Chiave

By Trading Economics

Entrata

191K

-51M

Vendite

6.7M

106M

EPS

-0.46

Margine di Profitto

-47.808

Dipendenti

1,784

EBITDA

-2.1M

-46M

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+49.94% upside

Dividendi

By Acuity

Utili prossimi

5 nov 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

805M

2.9B

Apertura precedente

28.84

Chiusura precedente

26.16

Notizie sul Sentiment di mercato

By Acuity

38%

62%

111 / 339 Classifica in Healthcare

Zai Lab Ltd ADR Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

4 set 2026, 23:40 UTC

News

DocuSign Inc. reported strong second-quarter results and raised guidance, yet shares are trading lower in after-market hours amid valuation concerns and economic context.

4 set 2026, 23:35 UTC

News

AAP shares lower in after-market hours on analyst rating updates.

4 set 2026, 23:27 UTC

News

Photronics Inc shares traded lower in after-market hours amid a securities class action lawsuit alleging fraud related to its product pipeline and demand stability.

4 set 2026, 23:20 UTC

News

Monster Beverage appoints Matthew S. Burroughs as Chief Accounting Officer and Deputy CFO, with shares rising in after-market trading.

4 set 2026, 23:10 UTC

News

Northrop Grumman was awarded a $508.49 million contract for flight test support by the U.S. Department of Defense, shares trading higher in after-market hours.

4 set 2026, 23:05 UTC

News

Pomerantz LLP filed a class action lawsuit against Replimune Group Inc for alleged securities fraud, contributing to a decline in shares during after-market hours.

4 set 2026, 23:02 UTC

News

Illumina Inc will join the S&P 500 index effective September 21, 2026, following an announcement by Dow Jones Indices. Shares are trading higher after the news.

4 set 2026, 23:02 UTC

Social Media
News

Star Bulk Carriers announced a parallel listing on Euronext Athens and an equity offering. Shares are lower in after-market hours following the news.

4 set 2026, 23:02 UTC

News

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

4 set 2026, 23:00 UTC

News

Bloom Energy shares are higher in after-market trading following its inclusion in the S&P 500, effective September 21, 2026.

4 set 2026, 23:00 UTC

News

FirstEnergy shares rise in after-market trading following Potomac Edison's $52.8 million rate adjustment proposal to enhance electric system reliability in Maryland.

4 set 2026, 23:00 UTC

News

Campbell's Co announced a restructuring plan, cutting 13% of salaried jobs and closing two plants. Shares are trading higher in after-market hours.

4 set 2026, 22:51 UTC

Correlated Moves
News

Shares rose in after-market trading amid strength in oil sector.

4 set 2026, 20:08 UTC

News

Planet Fitness Inc. is facing a securities class action lawsuit alleging misleading statements on customer growth, contributing to a decline in its stock during Friday's session.

4 set 2026, 20:08 UTC

News
Correlated Moves

Marten Transport Ltd shares are higher, supported by a broader transportation sector rally and an amended credit facility increasing the letters-of-credit sublimit to $50 million.

4 set 2026, 20:08 UTC

News

Jefferies Financial Group's shares are higher as it maintains "buy" ratings and raises price targets for several banks, including Barclays and Lloyds.

4 set 2026, 20:08 UTC

News

El Pollo Loco Holdings to participate in two investor conferences this month. Shares are trading higher, reflecting positive sentiment despite earlier session pullback.

4 set 2026, 20:08 UTC

News

Intuitive Surgical shares declined to $365.21, marking a four-week low. Ongoing market challenges contributed to the stock's downward movement during the session.

4 set 2026, 20:08 UTC

News
Social Media
Macro Event

McDonald's shares hit a 52-week low amid ongoing challenges, including high menu prices like $15 for an Egg McMuffin, reflecting a broader market decline.

4 set 2026, 20:08 UTC

News

OrthoPediatrics Corp shares are lower amid broader market declines and selling pressure following a strong jobs report. A major shareholder's recent sale adds to negative sentiment.

4 set 2026, 20:08 UTC

Social Media
Macro Event
News
Correlated Moves

Intel shares are higher as demand for CPUs surges, driven by AI workloads. Despite a price target cut to $92, investor sentiment remains positive.

4 set 2026, 20:08 UTC

News
Correlated Moves
Social Media

Advanced Micro Devices is rising as AI demand boosts projections for its EPYC CPUs, aided by partnerships like Microsoft’s Project Zenith.

4 set 2026, 20:08 UTC

News

Globus Medical Inc received CE mark approval for its Excelsius3D system, enabling sales in the EU and U.K. Shares are gaining during Friday's session.

4 set 2026, 20:08 UTC

News

PVH Corp reported a second-quarter loss of $102.9 million but shares are higher today, rebounding after an earlier dip during the session.

4 set 2026, 20:08 UTC

News
Correlated Moves

Douglas Dynamics declared a quarterly dividend of $0.295 per share, with shares rising today alongside Astec Industries' notable gain.

4 set 2026, 20:08 UTC

Macro Event
Social Media
News

Dell Technologies reported strong quarterly earnings, with revenue rising significantly. The stock reached a record high amid positive sentiment following the earnings beat.

4 set 2026, 20:08 UTC

News

Ollie's Bargain Outlet reported Q2 EPS of $1.42, surpassing estimates. Shares are higher amid positive sentiment following the earnings announcement.

4 set 2026, 20:08 UTC

News

Airbnb Inc. shares are declining as the EU proposes regulations on short-term rentals to address affordable housing shortages in tourist areas.

4 set 2026, 20:08 UTC

News

UnitedHealth Group will cut prior-authorization requirements across plans starting October 1. Shares are lower today, in line with broader market declines.

4 set 2026, 20:08 UTC

News

Teladoc Health Inc shares are lower today amid broader market declines following a strong jobs report raising concerns over tighter monetary policy.

Confronto tra pari

Modifica del prezzo

Zai Lab Ltd ADR Previsione

Obiettivo di Prezzo

By TipRanks

49.94% in crescita

Previsioni per 12 mesi

Media 39.33 USD  49.94%

Alto 45 USD

Basso 36 USD

Basato su 3 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Zai Lab Ltd ADR - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

3 ratings

3

Acquista

0

Mantieni

0

Vendi

Sentiment

By Acuity

111 / 339 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat